Becaplermin: Mechanism, Dosing & Research Data

Becaplermin (Regranex) is recombinant human platelet-derived growth factor BB (rhPDGF-BB), the first growth factor approved by the FDA for wound healing. It acts on PDGF receptor alpha and beta to stimulate chemotaxis and proliferation of repair cells in diabetic neuropathic ulcers. It was the first topical biologic approved for chronic wound management (1997) and remains the benchmark for growth factor-based wound therapy.

Mechanism of Action

Binds PDGFRbeta/PDGFRalpha and triggers receptor dimerization and tyrosine kinase autophosphorylation
Chemotaxis: PDGF-BB is the most potent chemotactic signal for neutrophils, monocytes, and fibroblasts; recruits repair cells to wound site
Proliferation: stimulates fibroblast and smooth muscle cell mitogenesis via PI3K/Akt and MAPK/ERK pathways
Collagen synthesis: PDGF-BB-stimulated fibroblasts upregulate procollagen I/III synthesis and MMP production for ECM remodeling
Angiogenesis: PDGF-BB recruits pericytes to nascent capillaries (PDGFR-beta on pericytes), stabilizing new vessels in granulation tissue

Research Findings

FDA approval (1997) based on Phase III trial: 30% becaplermin gel increased complete diabetic ulcer closure rate to 50% vs 35% placebo at 20 weeks
NNT of 6.3 for complete closure in diabetic neuropathic ulcers on the plantar surface
FDA black box warning (2008): patients using 3 or more tubes of becaplermin had increased cancer mortality in post-marketing surveillance (not confirmed in subsequent analyses)
Becaplermin combined with standard debridement outperforms standard care alone in multiple diabetic ulcer RCTs
PDGF-BB drives pericyte recruitment in tumor angiogenesis; anti-PDGFR therapy (imatinib) is used in some PDGF-driven tumors

Research Protocols

Diabetic ulcer (FDA-approved): 0.01% gel (100 mcg/g), apply thin layer once daily to clean debrided ulcer; cover with saline-moistened gauze; reassess at 10 weeks
Calculate dose: ulcer length x width x 0.6 = cm of gel per application (for tubes of 2 g, 7.5 g, or 15 g)
Preclinical: 1-10 mcg/mL PDGF-BB on fibroblast or SMC culture; proliferation by MTT; chemotaxis by Boyden chamber
Wound model: 1-3 mcg/cm2 applied to full-thickness excisional wound in db/db diabetic mice; histology at day 7 and 14

Interactions

Debridement: becaplermin requires a clean wound bed; necrotic tissue impairs growth factor efficacy
Collagenase/enzymatic debridement: sequential use (debride, then apply becaplermin) is standard clinical protocol
PDGFR inhibitors (imatinib, sunitinib): would antagonize becaplermin; avoid co-use in wound healing context

Safety Profile

FDA-approved topical agent. Black box warning for increased cancer mortality based on 3+ tube users in post-marketing; absolute risk increase small and may reflect severity of underlying disease. Local reactions (erythema, infection) in 2-5% of patients. Not for use in wounds with infection, necrosis, or active cancer.